Psivida (NSDQ:PSDV) shares surged today after the company said its Medidur drug-device combination met the primary endpoints in a Phase III clinical trial for treating posterior uveitis. Medidur uses the same injectable implant and drug as the Iluvien drug-device combo pSivida licensed to Alimera Sciences (NSDQ:ALIM) for treating diabetic macular degeneration. Iluvien won FDA approval in September […]
pSivida Corp.
Alimera surges on buyout rumors
(Reuters) — Alimera Sciences (NSDQ:ALIM), an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter. The company has reached out to investment banks to seek advice on how it would be valued in a potential sale and who the likely buyers would be, […]
pSividia eyes knee market, releases earnings
pSivida (NSDQ:PSDV) released its fiscal year earnings for 2015 yesterday and said it’s eyeing an entrance into the orthopedic knee market with a new drug-device implant. The company said it is slated to submit an investigational new drug application with the FDA and begin a study of a new implant using its Durasert technology to […]
Analyst says BSX may take CRM lead | Medtech Wall Street news for the week of September 29, 2014
Fourth time’s the charm: pSivida, Alimera jump on FDA nod for Iluvien
MRI Interventions taps Intuitive Surgical’s Grillo for CEO | Personnel Moves
pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review
UK regulators OK pSivida’s Iluvien
Third time’s no charm for pSivida, Alimera as FDA again denies Iluvien eye treatment
Alimera’s Iluvien vision repair implant wins national insurance coverage in France
The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.
Gamma Medica closes $18M Series A round | Wall Street Beat
Gamma Medica said it’s closed a $16 million Series A round from Psilos Group Managers.
The Northridge, Calif.-based company said it plans to use the cash to expand the commercial footprint of its LumaGen molecular breast imaging device and the LumaGuide biopsy model.